Gleason Score News and Research

RSS

Watchful waiting is viable option for many men with low risk prostate cancer

Active surveillance, also referred to as watchful waiting, is a viable option for many men with low risk prostate cancer although the concept continues to cause distress and confusion. James L. Mohler, MD, of Roswell Park Cancer Institute and chair of the NCCN Guidelines Panel for Prostate Cancer, discussed the role of active surveillance as well as other treatment options recommended in the recently updated NCCN Guidelines™ for Prostate Cancer at the NCCN 15th Annual Conference.

18 Mar 2010

DiagnoCure: Global studies confirm clinical utility of PROGENSA PCA3 test

DiagnoCure, Inc., a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced that the clinical utility of the PROGENSA(R) PCA3 test, developed and commercialized by its partner Gen-Probe, was confirmed in two large worldwide studies, conducted in a subset of patients in GlaxoSmithKline's REDUCE trial of dutasteride. The results demonstrate that PCA3 can help determine whether men suspected of having prostate cancer should undergo a repeat biopsy and can predict the risk of having an aggressive cancer.

8 Mar 2010

Study suggests routine evaluation does not predict prostate cancer

On the heels of the American Cancer Society's recent controversial response to breast and prostate cancer screenings guidelines, a new study from the Mayo Clinic has emerged analyzing the correlation between prostate-specific antigen (PSA) levels and prostate size. The study discovered that routine annual evaluation of prostate growth does not predict the development of prostate cancer.

24 Dec 2009

Lower total cholesterol may be caused by undiagnosed cancer: Study

A pair of studies in Cancer Epidemiology, Biomarkers & Prevention, lay to rest the decades-long concern that lower total cholesterol may lead to cancer, and in fact lower cholesterol may reduce the risk of high-grade prostate cancer.

4 Nov 2009

Men with lower cholesterol less likely to develop high-grade prostate cancer

Men with lower cholesterol are less likely than those with higher levels to develop high-grade prostate cancer - an aggressive form of the disease with a poorer prognosis, according to results of a Johns Hopkins collaborative study.

4 Nov 2009

Blood vessels good indicators of prostate cancer behavior

A diagnosis of prostate cancer raises the question for patients and their physicians as to how the tumor will behave. Will it grow quickly and aggressively and require continuous treatment, or slowly, allowing therapy and its risks to be safely delayed?

4 Nov 2009

New prostate cancer metastasis prediction method

Cancer experts at Johns Hopkins say a study tracking 774 prostate cancer patients for a median of eight years has shown that a three-way combination of measurements has the best chance yet of predicting disease metastasis.

1 Jul 2009

Research offers insight into why some prostate cancer returns

The majority of men who receive one of the standard treatments for localized prostate cancer - surgery or radiation therapy - have an excellent outcome.

27 May 2009

Low oxygen levels in prostate tumors can predict recurrence

Fox Chase Cancer Center researchers have discovered that low-oxygen regions in prostate tumors can be used to predict a rise in prostate-specific antigen (PSA) levels, a marker of tumor recurrence in prostate cancer.

17 May 2009

Statins can lower PSA levels in men with prostate cancer

Beyond lowering cholesterol, statin medications have been found to have numerous other health benefits, including lowering a healthy man's risk of developing advanced prostate cancer, as well as lowering his prostate-specific antigen (PSA) levels.

30 Apr 2009

AUA counters mainstream recommendations with new best practice statement on PSA testing

The American Urological Association (AUA) today issued new clinical guidance - which directly contrasts recent recommendations issued by other major groups - about prostate cancer screening, asserting that the prostate-specific antigen (PSA) test should be offered to well-informed, men aged 40 years or older who have a life expectancy of at least 10 years.

27 Apr 2009

Pomegranate juice may slow the progression of post-treatment prostate cancer recurrence

The two-stage clinical trial followed a total of 48 participants over six years. Eligible participants had a rising PSA after surgery or radiotherapy, a PSA greater than 0.2 ng/ml and less than 5 ng/ml and a Gleason score of 7 or less.

26 Apr 2009

Active surveillance can offer prostate cancer patients more individualized patient care

Active surveillance may be a viable option for some men, but reclassification of disease risk over time is imperative to ensure outcomes, according to researchers in Toronto, who will present these criteria during the 104th Annual Scientific Meeting of the American Urological Association (AUA).

26 Apr 2009

Selected men with low-risk prostate cancer have good clinical outcomes without immediate treatment

A multi-center study of prostate cancer patients appearing in today's Journal of Urology recommends that for some men diagnosed with low-risk prostate cancer, opting not to initially receive treatment can be safe if they are closely monitored.

16 Mar 2009

Male lumpectomy - first line treatment for prostate cancer

The so-called "male lumpectomy" - a minimally invasive interventional radiology treatment for prostate cancer - is as effective as surgery in destroying diseased tumors and can be considered a first-line treatment for patients of all risk levels and particularly those who have failed radiation, according to studies released at the Society of Interventional Radiology's 34th Annual Scientific Meeting.

10 Mar 2009

USA's largest ever prostate cancer screening program shows high compliance and consistent results

Just under five per cent of the men who took part in the prostate cancer element of the USA's largest ever cancer screening trial were diagnosed with the disease and the majority of those were picked up by screening programmes, according to research published in the December issue of the urology journal BJU International .

15 Dec 2008

Prostate cancer screening programme shows high compliance and consistent results in more than 38,000 men

15 Dec 2008

Seven elevated biomarkers predict prostate cancer risk with 86.6 percent reliability

A simple blood test screening for a panel of biomarkers can accurately predict whether a patient who has had prostate cancer surgery will have a recurrence or spread of the disease.

26 Jun 2008

Radiation therapy prolongs life in men with recurrent prostate cancer

Men whose tumors recur after prostate cancer surgery are three times more likely to survive their disease long term if they undergo radiotherapy within two years of the recurrence. Surprisingly, survival benefits were best in men whose new tumors were growing fastest, according to results of a 'look-back' study of 635 men by Johns Hopkins Medical Institutions researchers reported June 18 in the Journal of the American Medical Association.

17 Jun 2008

Henry Ford Hospital expands research on gene and radiation therapy for prostate cancer

Henry Ford Hospital is embarking on an expanded major clinical trial involving the use of gene therapy in combination with radiation therapy, to determine if the combined treatment is more effective than radiation therapy alone for patients with intermediate risk prostate cancer.

7 Feb 2008

Gleason Score News and Research

Watchful waiting is viable option for many men with low risk prostate cancer

DiagnoCure: Global studies confirm clinical utility of PROGENSA PCA3 test

Study suggests routine evaluation does not predict prostate cancer

Lower total cholesterol may be caused by undiagnosed cancer: Study

Men with lower cholesterol less likely to develop high-grade prostate cancer

Blood vessels good indicators of prostate cancer behavior

New prostate cancer metastasis prediction method

Research offers insight into why some prostate cancer returns

Low oxygen levels in prostate tumors can predict recurrence

Statins can lower PSA levels in men with prostate cancer

AUA counters mainstream recommendations with new best practice statement on PSA testing

Pomegranate juice may slow the progression of post-treatment prostate cancer recurrence

Active surveillance can offer prostate cancer patients more individualized patient care

Selected men with low-risk prostate cancer have good clinical outcomes without immediate treatment

Male lumpectomy - first line treatment for prostate cancer

USA's largest ever prostate cancer screening program shows high compliance and consistent results

Prostate cancer screening programme shows high compliance and consistent results in more than 38,000 men

Seven elevated biomarkers predict prostate cancer risk with 86.6 percent reliability

Radiation therapy prolongs life in men with recurrent prostate cancer

Henry Ford Hospital expands research on gene and radiation therapy for prostate cancer

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News